These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 27286599)

  • 1. Magic mushroom compound is a potential treatment for patients with major depression.
    Nurs Stand; 2016 Jun; 30(41):15. PubMed ID: 27286599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concise large-scale synthesis of psilocin and psilocybin, principal hallucinogenic constituents of "magic mushroom".
    Shirota O; Hakamata W; Goda Y
    J Nat Prod; 2003 Jun; 66(6):885-7. PubMed ID: 12828485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hallucinogenic mushrooms on the German market - simple instructions for examination and identification.
    Musshoff F; Madea B; Beike J
    Forensic Sci Int; 2000 Sep; 113(1-3):389-95. PubMed ID: 10978653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hallucinogenic mushrooms].
    Reingardiene D; Vilcinskaite J; Lazauskas R
    Medicina (Kaunas); 2005; 41(12):1067-70. PubMed ID: 16401965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychoactive mushrooms - an update].
    Supprian T; Frey U; Supprian R; Rösler M; Wanke K
    Fortschr Neurol Psychiatr; 2001 Dec; 69(12):597-602. PubMed ID: 11753749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin.
    Fricke J; Kargbo R; Regestein L; Lenz C; Peschel G; Rosenbaum MA; Sherwood A; Hoffmeister D
    Chemistry; 2020 Jul; 26(37):8281-8285. PubMed ID: 32101345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm potential of magic mushroom use: a review.
    van Amsterdam J; Opperhuizen A; van den Brink W
    Regul Toxicol Pharmacol; 2011 Apr; 59(3):423-9. PubMed ID: 21256914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological and chemical analysis of magic mushrooms in Japan.
    Tsujikawa K; Kanamori T; Iwata Y; Ohmae Y; Sugita R; Inoue H; Kishi T
    Forensic Sci Int; 2003 Dec; 138(1-3):85-90. PubMed ID: 14642723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms.
    Shoda T; Fukuhara K; Goda Y; Okuda H
    Drug Test Anal; 2011 Sep; 3(9):594-6. PubMed ID: 21960543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach.
    Agin-Liebes G; Davis AK
    Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Microscopic study of powders of hallucinogenic mushrooms--Psilocybe sp].
    Schäfer AT
    Arch Kriminol; 2000; 205(1-2):30-6. PubMed ID: 10726173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The determination of psilocin and psilocybin in hallucinogenic mushrooms by HPLC utilizing a dual reagent acidic potassium permanganate and tris(2,2'-bipyridyl)ruthenium(II) chemiluminescence detection system.
    Anastos N; Lewis SW; Barnett NW; Sims DN
    J Forensic Sci; 2006 Jan; 51(1):45-51. PubMed ID: 16423222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased global integration in the brain after psilocybin therapy for depression.
    Daws RE; Timmermann C; Giribaldi B; Sexton JD; Wall MB; Erritzoe D; Roseman L; Nutt D; Carhart-Harris R
    Nat Med; 2022 Apr; 28(4):844-851. PubMed ID: 35411074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psilocybin for Treatment-Resistant Depression.
    Østergaard SD; Hieronymus F
    N Engl J Med; 2023 Feb; 388(8):e22. PubMed ID: 36812443
    [No Abstract]   [Full Text] [Related]  

  • 17. Psilocybin for Treatment-Resistant Depression.
    Roméo B; Dervaux A; Benyamina A
    N Engl J Med; 2023 Feb; 388(8):e22. PubMed ID: 36812444
    [No Abstract]   [Full Text] [Related]  

  • 18. Psilocybin for Treatment-Resistant Depression.
    Lengvenyte A; Olié E; Courtet P
    N Engl J Med; 2023 Feb; 388(8):e22. PubMed ID: 36812445
    [No Abstract]   [Full Text] [Related]  

  • 19. Psilocybin for Treatment-Resistant Depression. Reply.
    Goodwin GM; Hellerstein DJ; Young AH
    N Engl J Med; 2023 Feb; 388(8):e22. PubMed ID: 36812446
    [No Abstract]   [Full Text] [Related]  

  • 20. Liquid chromatography-mass spectrometric and liquid chromatography-tandem mass spectrometric determination of hallucinogenic indoles psilocin and psilocybin in "magic mushroom" samples.
    Kamata T; Nishikawa M; Katagi M; Tsuchihashi H
    J Forensic Sci; 2005 Mar; 50(2):336-40. PubMed ID: 15813544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.